Guerbet and IBM Watson Health Announce Strategic Partnership for Artificial Intelligence in Medical Imaging, Liver
July 10 2018 - 2:30AM
The agreement aims
to develop and market software solutions to aid physicians' in
their treatment recommendations and follow-up care for liver
cancer.
Villepinte
(France) and Cambridge (USA) - July 10, 2018 (8:30 am CEST) -
Guerbet a global specialist in contrast agents and solutions for
diagnostic and interventional medical imaging, today announced that
it has signed an exclusive joint development agreement to develop
an artificial intelligence (AI) software solution in collaboration
with IBM Watson Health to support liver cancer diagnostics and
care.
Through this collaboration,
Guerbet and IBM Watson Health plan to co-develop innovative,
clinical decision support solutions. The first, called Watson
Imaging Care Advisor[1] for Liver,
is planned to be a diagnostic support tool that will use artificial
intelligence to automate the detection, staging, tracking,
monitoring, therapy prediction and therapy response of primary and
secondary liver cancer for clinicians. The IBM Research team will
also work on development of the solutions leveraging prior research
innovations.
Liver cancer is the second leading
cause of cancer death worldwide,[2] and the
fastest growing cause of cancer deaths in the United
States.[3] About 83
percent of primary liver cancer cases occur in developing
countries.[4] The liver
is also a common site for metastases, particularly in the case of
digestive cancers, in which nearly 50% of patients develop
metastases.[5] The hope is
that better characterization and earlier identification of these
metastases may lead to an improvement in the chances of
recovery.
"Liver cancer is a growing health
concern globally, and the use of augmented intelligence by medical
imaging is well positioned to help address it. We are proud to work
with IBM Watson Health to develop a solution dedicated to liver
disease, which could help make it possible for clinicians to make
more informed characterizations of tissue without recourse to
biopsy," said Yves L'Epine, Guerbet's CEO.
Care Advisor for Liver will be
designed to be compatible with the most common PACS visualization
systems, making it easy to be integrated directly into the
workflows of healthcare professionals.
"Imaging is a critical area of
healthcare where we believe artificial intelligence can be used to
expand the physician's view so they can be more informed in their
diagnostic and treatment decisions for their patients. We are
excited to bring together the significant respective expertise of
IBM and Guerbet to advance innovation in this important field, and
ultimately help combat the challenge of liver cancer globally,"
said Anne Le Grand, Vice President of Imaging at Watson Health.
Watson Imaging Care Advisor for
Liver will be a part of a family of decision support tools powered
by IBM Watson image analytics designed to inform radiologists'
diagnostic decisions for their patients. These offerings are being
developed with a shared objective to create insights derived from
IBM Watson image analytics to help inform clinical decisions.
"We look forward to working with
IBM Watson Health on Guerbet's first project aimed at better
assisting radiologists with augmented intelligence. This will help
us grow our capabilities in AI to enable innovative solutions
improving care pathways." said François Nicolas, Chief Digital
Officer at Guerbet.
Guerbet is a pioneer in the
contrast-agent field, with more than 90 years' experience, and is a
leader in medical imaging worldwide. It offers a comprehensive
range of pharmaceutical products, medical devices and services for
diagnostic and interventional imaging, to improve the diagnosis and
treatment of patients. With 8% of revenue dedicated to R&D and
more than 200 employees distributed amongst its centers in France,
Israel and the United States, Guerbet is a substantial investor in
research and innovation. Guerbet (GBT) is listed on Euronext Paris
(segment B - mid caps) and generated €807 million in revenue in
2017. For more information about Guerbet, please visit
www.guerbet.com
Watson Health is a business unit
of IBM that is dedicated to the development and implementation of
AI and data-driven technologies to advance health. Watson Health
technologies are tackling a wide range of the world's biggest
healthcare challenges including cancer, diabetes, drug discovery
and more. Learn more at ibm.com/watson/health
Guerbet
Global
Alize RP
Caroline Carmagnol & Wendy Rigal
+33 (0)1 44 54 36 66 /
+33 (0)6 48 82 18 94
guerbet@alizerp.com |
|
IBM Watson
Health
Jessica Emond
+1 202-257-1808
Jessica.emond@ibm.com
[1] Care
Advisor is not yet a formally approved product name.
[2]
http://www.who.int/news-room/fact-sheets/detail/cancer
[3]
http://pressroom.cancer.org/LiverCancer2017
[4]
https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics
[5]
https://www.sciencedirect.com/science/article/pii/S2211568414000941
Press Release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024